Albertson's LLC Assigned 'B' Corporate Credit Rating; Debt Rated 'BB-' Feb 13

  • ID: 2403519
  • February 2013
  • Standard & Poors
1 of 3

Albertson's LLC is purchasing Albertsons bannered stores, currently operated by SUPERVALU Inc., and is procuring a $1.05 billion term loan and a $1 billion asset based credit facility to partially fund the purchase. We expect more competitive pricing at the acquired stores to lead to margin pressures over the next year at the company. We are assigning a 'B' corporate credit rating to Albertson's LLC and a 'BB-' issue level rating and '1' recovery rating to the company's proposed $1.05 billion term loan and $1 billion asset based revolving credit facility. The negative rating outlook reflects the possibility of profit decreases to be greater than we expect, especially if the new pricing and merchandising strategies do not change the performance...

Companies mentioned in this report are:
- Albertson's LLC

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Albertson's LLC

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.